B2M and cancer: In a subgroup of 19 HLA-A*02:01- and MAGE-A4 double-positive patients, most tumors (63%) were also positive for MHC class I and B2M (Supplementary Figure 3), indicating that these tumors are competent in antigen presentation which is crucial when targeting intracellular proteins through cancer immunotherapy.